- Home
- EDIT vs ZIMV Comparison
EDIT vs ZIMV Comparison
Compare EDIT & ZIMV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- ZIMV
- Stock Information
- Founded
- EDIT 2013
- ZIMV 2021
- Country
- EDIT United States
- ZIMV United States
- Employees
- EDIT N/A
- ZIMV N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- ZIMV Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- EDIT Health Care
- ZIMV Health Care
- Exchange
- EDIT Nasdaq
- ZIMV Nasdaq
- Market Cap
- EDIT 263.7M
- ZIMV 262.9M
- IPO Year
- EDIT 2016
- ZIMV N/A
- Fundamental
- Price
- EDIT $2.28
- ZIMV $18.84
- Analyst Decision
- EDIT Buy
- ZIMV Hold
- Analyst Count
- EDIT 12
- ZIMV 3
- Target Price
- EDIT $6.20
- ZIMV $14.50
- AVG Volume (30 Days)
- EDIT 2.2M
- ZIMV 1.2M
- Earning Date
- EDIT 08-19-2025
- ZIMV 07-30-2025
- Dividend Yield
- EDIT N/A
- ZIMV N/A
- EPS Growth
- EDIT N/A
- ZIMV N/A
- EPS
- EDIT N/A
- ZIMV N/A
- Revenue
- EDIT $35,837,000.00
- ZIMV $443,402,000.00
- Revenue This Year
- EDIT N/A
- ZIMV $2.09
- Revenue Next Year
- EDIT N/A
- ZIMV $1.64
- P/E Ratio
- EDIT N/A
- ZIMV N/A
- Revenue Growth
- EDIT N/A
- ZIMV N/A
- 52 Week Low
- EDIT $0.91
- ZIMV $8.15
- 52 Week High
- EDIT $4.90
- ZIMV $18.98
- Technical
- Relative Strength Index (RSI)
- EDIT 43.28
- ZIMV 85.28
- Support Level
- EDIT $2.37
- ZIMV $18.76
- Resistance Level
- EDIT $2.67
- ZIMV $18.90
- Average True Range (ATR)
- EDIT 0.23
- ZIMV 0.12
- MACD
- EDIT -0.08
- ZIMV -0.06
- Stochastic Oscillator
- EDIT 5.37
- ZIMV 60.61
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About ZIMV ZimVie Inc.
ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions. Business is organized into two operating segments the spine products segment and the dental products segment.